Oncolytic Virus Overcomes 'Intravenous Administration' Challenge... ShinlaGen SJ-650 Poised as Global Game Changer
Research Findings Published in a Prestigious International Journal
ShinlaGen's next-generation oncolytic virus platform, SJ-650, has published its research results in the prestigious scientific journal "Molecular Therapy," and has been recognized by the international academic community for its potential to become a "game changer" in the field of oncolytic viruses. This publication goes beyond academic achievement, as it is evaluated to have presented a solution to intravenous administration, which has long been considered the biggest challenge in the field of oncolytic viruses.
According to the industry on April 3, existing oncolytic virus therapeutics have relied on local administration by injecting directly into tumors. This is because the body's immune system, including complement and neutralizing antibodies, recognizes viruses as invaders and eliminates them. This has fundamentally limited the treatment of metastatic cancers that have spread throughout the body or deep-seated cancers located deep within tissues. However, ShinlaGen has overcome this with an innovative design that expresses the complement regulatory protein CD55 on the virus surface. This sophisticated mechanism, which allows the virus to withstand immune attacks in the bloodstream and be stably delivered to tumor tissue, is drawing attention as a core technology that could shift the paradigm of oncolytic virus therapy.
ShinlaGen is being credited for proving the technical value of SJ-650 with this research data. According to the published paper, SJ-650 maintained approximately nine times higher survival compared to existing oncolytic virus therapies, even in environments with neutralizing antibodies, and demonstrated efficacy by killing the majority of tumor cells within 24 hours after being delivered to the tumor via the bloodstream.
Notably, in animal models of metastatic cancer, SJ-650 reduced more than 90% of total tumor mass. In contrast, in normal tissues, even after more than 20 repeated administrations, there were no significant signs of systemic toxicity, and no cell death was observed, establishing robust safety indicators for future clinical applications.
Furthermore, in this study, ShinlaGen proactively secured "human-relevance" data, which the U.S. Food and Drug Administration (FDA) has recently emphasized as a key criterion for Investigational New Drug (IND) approval, thereby enhancing clinical significance. SJ-650 maintained significantly higher survival compared to existing oncolytic virus therapies in serum experiments using samples from actual patients with vaccinia virus antibodies, demonstrating reproducibility of its immune evasion mechanism. This serves as a key indicator suggesting a high likelihood of success in actual human administration beyond laboratory studies, and is expected to become solid scientific evidence in future global clinical approvals and technology out-licensing negotiations.
ShinlaGen is currently focusing its organizational capabilities on translating these academic achievements into tangible commercial results. The company is working with global CDMO company RayThera to optimize manufacturing processes and build a mass production base for the virus, and plans to engage with global companies based on the validated efficacy data.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A ShinlaGen representative stated, "Through this publication, the unique mechanism and technological maturity of SJ-650 have been objectively validated by the international academic community," and added, "We will pursue a multifaceted strategy for technology transfer discussions based on the data we have acquired."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.